Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in maintenance hemodialysis patients with osteoporosis
ChiCTR2400088032Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Southern Medical University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of denosumab in osteoporosis, chronic kidney disease-mineral and bone disorder (CKD-MBD) and end-stage kidney disease (ESKD) (2 arms), sponsored by The Third Affiliated Hospital of Southern Medical University. Primary endpoint: Fracture incidence. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosischronic kidney disease-mineral and bone disorder (CKD-MBD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2400088032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088032.